Verisense announce opening of Digital Biobank

August 14, 2024
Research and Development AI, Devices, Diagnostics, Verisense, artificial intelligence, digital health, machine learning

This week, Verisense have announced that their Digital Biobank, with data from over one million people, is open for business.

China CDE clears Phase 3 Study of Lisafltoclax in Newlly Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome

August 13, 2024
Clinical Research, Research and Development Ascentage Pharma, Oncology

The China Centre for Drug Evaluation (CDE) has cleared the registrational phase 3 study of lisaftoclax in combination with azacitadine …

Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

August 13, 2024
Clinical Trial Services, Research and Development Immunology, Pfizer, autoimmune, clinical trial, respiratory, vaccines

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical trial into the safety and …

nasal-spray-drawing

First Nasal Spray for Treatment of Anaphylaxis approved by FDA

August 12, 2024
Research and Development Emergency Medicine, FDA, anaphylaxis, epinephrine, nasal

ARS Pharmaceuticals has been granted approval by the US Food and Drug Administration (FDA) for their epinephrine nasal spray, neffy, …

acute_leukemia-all

Merck to acquire Curon Biopharmaceuticalโ€™s B-Cell Depletion Therapy

August 12, 2024
Research and Development Corporate, Curon Biopharmaceuticals, Merck, Oncology, b-cells

Merck have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire CN201, a …

Richmond promotes new Director of Communications and Participant Engagement

August 9, 2024
Research and Development Corporate, Richmond Pharmacology, appointment, pharmaceutical

Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and …

Janssenโ€™s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine

August 9, 2024
Research and Development Haematology, Janssen, New England Journal of Medicine, Obstetrics & Gynaecology, foetus, newborn, women's health

Johnson & Johnson company Janssen has announced that the results from its phase 2 trial into nipocalimab have been published …

Cresset collaborates with global leaders Enamine to enable the design of new Targeted Protein Degradersย 

August 9, 2024
Research and Development Corporate, Cresset, Cressete, Enamine, Microbiology, Targeted Protein Degraders

This week, drug discovery company Cresset has announced the extension of its global collaboration with chemical and biological contract research …

Pharma services boom in China as CPHI & PMEC China posts record attendance

August 8, 2024
Conferencing, Events & Incentives, Public Relations, Sales and Marketing CPHI China, PMEC China, pharma

Domestic and international markets in Asia surging as CPHI & PMEC China welcomes a staggering 93,000 attendees 08 August, 2024, …

Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

August 7, 2024
Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …

Alzheimer's brain

Sangamo Therapeutics and Genentech team up to develop genomic medicines for neurodegenerative diseases

August 7, 2024
Research and Development Genentech, Neurology, Sangamo Therapeutics, genomic medicine, neurodegenerative diseases

Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to …

New Real-World Data Published in Journal of Cardiac Failureย on Effectiveness

August 6, 2024
Research and Development Cardiac, Cardiology, Pfizer

Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. Walton Oaks, 6th August …

Rheumatoid arthritis

Positive results announced for Leviceptโ€™s moderate-to-severe osteoarthritis treatment

August 6, 2024
Research and Development Levicept, Rheumatology, osteoarthritis, trial

Biotechnology company Levicept has announced positive results from its phase 2 trial into LEVI-04, for the treatment of osteoarthritis.

Brain picture

Clinical trials for personalised cancer vaccine used to tackle aggressive brain tumours in young adults and adolescents launched by UCLA Health

August 6, 2024
Research and Development Oncology, UCLA Health, adolescent cancer, brain tumour, cancer vaccine, clinical trial

Today, researchers at theย UCLA Health Jonsson Comprehensive Cancer Center have announced that they are launching a first-of-its-kind clinical trial to …

Levosertยฎ (52mg levonorgestrel intrauterine system [IUS]) receives an 8-year licence extension in the UK for contraception

August 5, 2024
Research and Development Contraception, UK, contraception, license extension

Gedeon Richter UK Ltd. (โ€œRichterโ€) today announced that the Medicines Health Regulatory Authority (MHRA) has authorised an extension to the …

US FDA expandsย Jemperliย (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

August 5, 2024
Research and Development GSK, Oncology, Reproductive health, endometrial cancer

PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approvedย Jemperliย (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …

Johnson & Johnsonโ€™s MedTech announce orthopaedics receives 501K clearance from FDA for spinal robotics and navigation platform

August 5, 2024
Research and Development 501k clearance, Johnson & Johnson MedTech, Orthopaedics, orthopaedics, robotics, spinal, surgery

Today, the Orthopaedics branch of Johnson & Johnson MedTech, DePuy Synthes, has announced that their surgical robotics system VELYS active …

brainss

Abbvie acquires Cerevel Therapeutics

August 2, 2024
Mergers and Acquisitions AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson's disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia

Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple programmes across neurological and psychiatric …

Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour

August 2, 2024
Medical Communications Adaptimmune, Oncology, accelerated approval, engineered cell therapy, oncology, synovial sarcoma

Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given accelerated approval for TECELRA (afamitresgene …

The Gateway to Local Adoption Series

Latest content